Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus XULTOPHY 100 3 6.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus XULTOPHY 100 3 6.
CYCLOSET vs XULTOPHY 100/3.6
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Xultophy 100/3.6 is a combination of insulin degludec (a long-acting basal insulin analog) and liraglutide (a GLP-1 receptor agonist). Insulin degludec binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production. Liraglutide activates GLP-1 receptors, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Subcutaneous injection once daily, starting at 10 units (10 units insulin degludec and 3.6 mcg liraglutide). Titrate by 2 units every 3-4 days based on fasting plasma glucose to a maximum of 50 units daily.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Insulin degludec: ~25 hours (range 22-28 hours); liraglutide: ~13 hours. The ultra-long half-life of insulin degludec allows once-daily dosing with flat activity profile.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Renal: insulin degludec and liraglutide are cleared primarily via degradation, with less than 2% excreted unchanged renally. Fecal: negligible.
Category C
Category C
Dopamine Agonist / Antidiabetic
Antidiabetic